<- Go Home

Life Technologies Corporation

Life Technologies Corporation operates as a life sciences company. The company’s Research Consumables business group offers molecular and cell biology reagents, endpoint PCR, and other benchtop instruments and consumables, such as RNAi, DNA synthesis, sample prep, transfection, cloning and protein expression profiling and protein analysis, cell culture media used in research, stem cells and related tools, cellular imaging products, antibodies, and cell therapy related products. Its Genetic Analysis business group provides capillary electrophoresis (CE) instruments used for research applications and various CE consumables; real-time and digital qPCR instruments used in research applications; qPCR consumables and genomic assays; and sequencing systems and reagents for the SOLiD and Ion Torrent systems. The company’s Applied Sciences business group offers bioproduction, forensics, and animal health and food safety reagent kits; CE; and qPCR instruments that are used in applied markets applications; and medical sciences products consisting of molecular diagnostics products and services. Life Technologies Corporation also provides repair and maintenance services; and custom services, such as cell line development, custom media modification, and primers and custom assays development services. Its products offer research tools for genomics studies, proteomics studies, gene splicing, cellular analysis, and other research applications required by laboratories associated with universities, medical research centers, and government and other research institutions, as well as biotechnology, pharmaceutical, and chemical companies. The company was formerly known as Invitrogen Corp. and changed its name to Life Technologies Corporation in November 2008. The company was incorporated in 1997 and is headquartered in Carlsbad, California. Life Technologies Corporation operates as a subsidiary of Erie N2 Uk Limited.

Market Cap

$13.1B

Volume

2.3M

Cash and Equivalents

$336.4M

EBITDA

$1.2B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$2.5B

Profit Margin

65.67%

52 Week High

$76.10

52 Week Low

$56.67

Dividend

N/A

Price / Book Value

2.64

Price / Earnings

28.00

Price / Tangible Book Value

-15.55

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

$805.6M

Return on Equity

9.91%

Return on Assets

5.91

Cash and Short Term Investments

$354.2M

Debt

$2.1B

Equity

$5.0B

Revenue

$3.8B

Unlevered FCF

$848.7M

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches